<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01854229</url>
  </required_header>
  <id_info>
    <org_study_id>PAS-01</org_study_id>
    <nct_id>NCT01854229</nct_id>
  </id_info>
  <brief_title>Prometra Post-Approval Study</brief_title>
  <official_title>A Prospective, Non-randomized, Open-label, Multicenter Study to Evaluate the Long-term Safety of the Prometra Programmable Pump System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flowonix Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flowonix Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Prometra Pump is approved by the FDA for use in the United States. The purpose of this
      study is to collect long-term safety data on the Prometra Pump.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is proposed under part of the post-Premarket Approval (PMA) requirements. This
      study is a prospective, non-randomized, open-label, multicenter study. It will be performed
      at 10-30 centers in the US and enroll a maximum of 400 subjects. Subjects will be followed
      for a total of five years.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <start_date type="Actual">June 20, 2013</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of granuloma formation</measure>
    <time_frame>Five years</time_frame>
    <description>The primary hypothesis is that the 5-year rate of patients with granuloma formation will be noninferior to that in the literature. The literature rate was found to be approximately 3% and the noninferiority margin will be three percentage points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pump failure</measure>
    <time_frame>Five years</time_frame>
    <description>Tabulation of pump failures, including time to occurrence and type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pump battery life</measure>
    <time_frame>Five years</time_frame>
    <description>Tabulation of occurences of premature pump battery depletions</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Device-related adverse events</measure>
    <time_frame>Five years</time_frame>
    <description>Tabulation of device-related adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Device-related serious adverse events</measure>
    <time_frame>Five years</time_frame>
    <description>Tabulation of device-related serious adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of granuloma formation by race and ethnicity</measure>
    <time_frame>Five years</time_frame>
    <description>The effect of race and ethnicity on granuloma formation</description>
  </other_outcome>
  <other_outcome>
    <measure>Granuloma formation by drug type</measure>
    <time_frame>Five years</time_frame>
    <description>The effect of alternative drugs on granuloma formation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Chronic Pain</condition>
  <condition>Cancer Pain</condition>
  <condition>Intractable Pain</condition>
  <condition>Back Pain</condition>
  <arm_group>
    <arm_group_label>Prospective pump candidates</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>New candidates who will receive the Prometra Programmable Intrathecal Infusion Pump</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Previous IDE study subjects continuing with the therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who were part of the previous IDE study, still have an active Prometra Programmable Intrathecal Infusion Pump, and are willing to continue in a study protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prometra Programmable Intrathecal Infusion Pump</intervention_name>
    <description>There are two enrollment groups (arms). One is for new patients who are going to have a Prometra Pump implanted. The other arm is for patients who were part of the IDE study prior to FDA approval of the pump, and are willing to continue to be followed as part of a study.</description>
    <arm_group_label>Prospective pump candidates</arm_group_label>
    <arm_group_label>Previous IDE study subjects continuing with the therapy</arm_group_label>
    <other_name>Flowonix pump</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient meets at least one of the following:

               -  is suffering from malignant pain (i.e., cancer pain)

               -  has chronic, non-malignant pain

               -  subject was enrolled in PUMP I or PUMP II study and chooses to participate in
                  this Post-Approval study

               -  Patient with an existing implantable pump for pain therapy that requires
                  replacement

          2. Patient is at least 22 years of age.

          3. Investigator considers the patient to be able and willing to fulfill all study
             requirements.

          4. Patient has provided written informed consent to participate in the study.

        Exclusion Criteria:

          1. Patient meets any of the contraindications for use of the Prometra System

          2. Patient has a prior history of granuloma formation, or is receiving treatment for a
             suspected granuloma.

          3. Patient is pregnant or breast-feeding or is of child-bearing potential and not
             employing effective birth control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Matis</last_name>
    <role>Study Director</role>
    <affiliation>Flowonix Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Diego Comprehensive Pain</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Pain Physicians</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Pain Alliance</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PIH Health Pain Management</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Pain &amp; Headache Treatment Center</name>
      <address>
        <city>Derby</city>
        <state>Connecticut</state>
        <zip>06418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRC Associates</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Institute of Medical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32257</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Pain Management</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Pain Relief Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Scientific Innovations</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Pain Management</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Institute</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interventional Pain Management Specialists</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluegrass Pain Consultants</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentuckiana Pain Specialists</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuroscience and Pain Institute</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Pain and Neuroscience</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Anesthesia Pain Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Pain Consultants</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triumph Medical</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Pain Solutions</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219-1531</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pain Management Institute</name>
      <address>
        <city>Wooster</city>
        <state>Ohio</state>
        <zip>44691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurospine Institute</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pain Care of Oregon</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Pain Management Associates</name>
      <address>
        <city>Trevose</city>
        <state>Pennsylvania</state>
        <zip>19053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deborah Fisher, MD, PA</name>
      <address>
        <city>Sherman</city>
        <state>Texas</state>
        <zip>75090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Space City Pain Specialist</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nexus Pain Care</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.aapainmanage.org/</url>
    <description>American Academy of Pain Management</description>
  </link>
  <link>
    <url>http://www.painmed.org/</url>
    <description>American Academy of Pain Medicine</description>
  </link>
  <link>
    <url>http://www.neuromodulation.org/</url>
    <description>North American Neuromodulation Society</description>
  </link>
  <link>
    <url>http://www.worldinstituteofpain.org/site/home.php</url>
    <description>World Institute of Pain</description>
  </link>
  <link>
    <url>http://www.asra.com/</url>
    <description>American Society of Regional Anesthesia and Pain Medicine</description>
  </link>
  <reference>
    <citation>Rauck R, Deer T, Rosen S, Padda G, Barsa J, Dunbar E, Dwarakanath G. Long-term follow-up of a novel implantable programmable infusion pump. Neuromodulation. 2013 Mar-Apr;16(2):163-7. doi: 10.1111/j.1525-1403.2012.00515.x. Epub 2012 Oct 11.</citation>
    <PMID>23057877</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2013</study_first_submitted>
  <study_first_submitted_qc>May 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2013</study_first_posted>
  <last_update_submitted>April 7, 2018</last_update_submitted>
  <last_update_submitted_qc>April 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Morphine</keyword>
  <keyword>Implantable Infusion Pumps</keyword>
  <keyword>Intrathecal Pump</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Cancer Pain</mesh_term>
    <mesh_term>Pain, Intractable</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

